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1  |  INTRODUC TION
Mesenchymal stromal cells (MSCs) were first described by 
Friedenstein et al. as bone marrow cells with fibroblastic morphol-
ogy and osteogenic character.1,2 This non- hematopoietic undiffer-
entiated cell population derives from the mesoderm with clonogenic 
character and has proved able to adhere to plastic in in vitro cultures. 
The main characteristics of MSCs are their colony- forming capac-
ity, adherence to plastic, expansion in in vitro cultures, and their 
pluripotential character, conferring them with potential osteogenic, 
adipogenic and chondrogenic capacities. They are also characterized 
by certain surface markers, showing positive CD44, CD73, CD90 
and CD105 expression and negative CD14, CD11b, CD19, CD79a, 
CD34, CD45 and HLA- DR expression.3– 8
MSCs have been isolated from peripheral blood, umbilical cord, 
amniotic fluid, placenta, and articular cartilage, among other tis-
sues.9– 15 However, hematopoietic and adipose tissues are the most 
widely used sources due to their easier availability and processing.5,10
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Abstract
Mesenchymal stromal cells (MSCs) have evidenced considerable therapeutic poten-
tial in numerous clinical fields, especially in tissue regeneration. The immunological 
characteristics of this cell population include the expression of Toll- like receptors and 
mannose receptors, among others. The study objective was to determine whether 
MSCs have phagocytic capacity against different target particles. We isolated and 
characterized three human adipose tissue MSC (HAT- MSC) lines from three patients 
and analysed their phagocytic capacity by flow cytometry, using fluorescent latex 
beads, and by transmission electron microscopy, using Escherichia coli, Staphylococcus 
aureus and Candida albicans as biological materials and latex beads as non- biological 
material. The results demonstrate that HAT- MSCs can phagocyte particles of differ-
ent nature and size. The percentage of phagocytic cells ranged between 33.8% and 
56.2% (mean of 44.37% ± 11.253) according to the cell line, and a high phagocytic 
index was observed. The high phagocytic capacity observed in MSCs, which have 
known regenerative potential, may offer an advance in the approach to certain local 
and systemic infections.
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MSCs have multiple clinical applications, mainly in regenerative 
medicine, through their capacity to migrate to the focus of damaged 
tissue and induce its repair or replacement; this capacity derives 
from their pluripotentiality and their secretion of bioactive sub-
stances that can act at both local and systemic level.16– 18 MSCs have 
also been attributed with potent immunomodulatory properties that 
may be useful to control inflammation and tissue damage.19 They 
express certain Toll- like receptors (TLRs), mannose receptors (MRs) 
and scavenger receptors (SRs), indicating a possible role against in-
fection, although this has yet to be confirmed.20– 23 Also, MSCs seem 
to have the capacity to induce the phagocytic activity of other cells, 
such as polymorphonuclear cells or alveolar macrophages by releas-
ing.24,25 Some other authors have even suggested the use of MSCs in 
sepsis, through its action at different levels, such as its ability to lo-
cate to damage tissue, secrete paracrine signals to systemic and local 
inflammation, decrease apoptosis, promote neoangiogenesis, stimu-
late immune cells and show antimicrobial activity.26 Later, Khan et al. 
reported that MSCs are new phagocytic cells with a high potential 
for immunotherapy in the treatment of tuberculosis.23
The isolation, culture, identification, differentiation, function and 
regenerative capacity of MSCs have been widely studied, prompt-
ing considerable interest in their potential therapeutic usefulness 
in different diseases. In fact, they are among the most frequently 
used cell types in regenerative medicine, with numerous clinical 
applications.23,27– 29
Human adipose tissue MSCs (HAT— MSCs) are found in the stromal 
vascular fraction of subcutaneous adipose tissue. When the cells of this 
vascular fraction are cultivated in the required culture medium, both ad-
ipose stem cells and stromal vascular fraction cells can be obtained.30,31 
HAT- MSCs have been used for years in regenerative plastic surgery.31,32 
In the same way, these cells have also been used for the treatment of 
anal fistulas, diabetic foot, alopecia and certain defects in soft tissues 
such as healing processes, among others.31,33– 36 Thus, it has also been 
possible to demonstrate the regenerative capacity of HAT- MSCs in 
combination with platelet- rich plasma in soft tissue regeneration and 
wound healing.32,37 On the contrary, the anti- inflammatory and immu-
nomodulatory potential of this cell population has been pointed out as 
a possible cell therapy in infection caused by the SARS- CoV- 2 virus.38
With this background, the objective of this study was to determine 
the phagocytic capacity of MSCs by means of two study techniques 
(flow cytometry and transmission electron microscopy), using target 
particles of different size and origin, such as latex beads and microor-
ganisms. This will contribute to the knowledge of the physiology of this 
cell population.
2  |  MATERIAL AND METHODS
2.1  |  Ethical procedures
This study was approved by the Ethical Committee for Biomedical 
Research of Granada, Spain (CEIM/CEI Granada; Reg. code 1491- 
N- 18) and by the Coordinating Committee of Ethical Biomedical 
Research of the Andalusian Autonomous Community (CCEIBA; Reg. 
code VJCR 16/41141). This approval was granted for the collection 
and processing of tissue samples. Procedures were performed in ac-
cordance with the 1964 Helsinki declaration (Ethical Principles for 
Medical Research Involving Human Subjects) and its 7 later amend-
ments. Informed consent was signed by all donors.
2.2  |  Establishment of human adipose tissue MSCs
HAT- MSC lines were isolated from three adipose tissue samples 
from two females aged 40 and 47 years and one male aged 52 years. 
Cells were provided by the Tissue Bank (Biobank) of the Andalusian 
Public Health System. All three patients signed their informed con-
sent to the study of their samples. Samples were digested as fol-
lows: after initial washing with phosphate- buffered saline (PBS), 
they were ground and then treated with 0.15% collagenase type I 
(Sigma, USA) for 60 min at 37°C under agitation with a double mixer. 
Collagenase was subsequently inactivated by using basal culture 
medium (Dulbecco's Modified Eagle's Medium supplemented with 
10% foetal bovine serum [FBS]: DMEM + 10% FBS) and centrifuging 
for 10 min at 309 g. The sediment was suspended in DMEM + 10% 
FBS, and the cell suspension obtained was cultured in 75- cm2 cul-
ture flasks at a density of 2 × 103 cells/cm2 at 37°C in 5% CO2 atmos-
phere under standard conditions.39,40
Adherent cells were washed at 48 h with fresh medium and cul-
tured at 37°C and 5% CO2, changing the culture medium three times 
a week. Passage 1 was performed once 85%– 90% cell confluence 
was obtained (7– 10 days), typifying the cell line by flow cytome-
try to ensure the presence of MSC- characteristic surface markers 
(monoclonal antibody from BD Pharmigen TM, Madrid, Spain) with 
positivity for CD44, CD73, CD90 and CD105 and negativity for 
CD11b, CD19, CD45 and HLA- DR (Table S1). At the same passage, 
cells were differentiated to osteogenic and adipogenic lineage, fol-
lowing the protocol of Zajdel et al.41 and Munir et al.42 respectively.
For the experiments, cells from each donor were used at pas-
sages 3– 4.
2.3  |  Study of phagocytic capacity
The phagocytic capacity of HAT- MSCs was analysed by flow cytom-
etry and transmission electron microscopy.
2.3.1  |  Flow cytometry
Phagocytic activity was studied by flow cytometry. Cultures of HAT- 
MSC were detached from the cultured flask at passage 3 or 4 using a 
solution of 0.05% (w/v) trypsin and 0.02% (w/v) EDTA and were then 
washed and suspended in complete culture medium with 20% FBS at 
1 × 106 cells/ml. One hundred microliters of cell suspension was incu-
bated with 2 μl carboxylated FICT- labelled latex beads (Sigma Aldrich, 
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St Louis, USA) of 2 μm diameter, for 30 min at 37°C in darkness. Cells 
were washed, suspended in 1 ml PBS and immediately analysed in flow 
cytometer (FASC Canto II [software Diva 6 V3.1], Becton Dickinson 
Palo Alto, California, USA). Control assays were carried out at 4°C. 
The percentage of fluorescence cells was calculated from counts of 
2000 to 3000 cells. Results were obtained as the percentage of cells 
positive for phagocytosis and the mean channel fluorescence, which 
correlates with the number of particles phagocytosed.43
2.3.2  |  Transmission electron microscopy
HAT- MSC phagocytic activity was also analysed by transmission 
electron microscopy. At passages 3– 4, cells were placed in 6- well 
plates at a concentration of 2 × 104 cells/ml and cultured in medium 
with 20% FBS at 37°C in 5% CO2 atmosphere. The culture medium 
was removed at 24 h, adding 5 ml fresh medium to each well. Next, 
10 µl of DMEM + 10% FBS suspension containing target particles 
was added to the test wells and 10 µl of DMEM + 10% FBS alone 
to the control wells. Suspensions of the target particles (latex, 
Escherichia coli, Staphylococcus aureus and Candida albicans) were 
prepared in complete culture medium, always adjusted to 0.5 of the 
McFarland turbidity standard scale43 and then cultured at 37°C in 5% 
CO2 atmosphere. Cells were then cultured and treated following the 
protocol described by Ruiz et al.44
2.4  |  Statistical analysis
R software (version 2.9.2, Auckland, New Zealand) was used for data 
analyses of phagocytosis by flow cytometry. Phagocytic capacity 
was compared using the Student's t test. p ≤ 0.05 was considered 
statistically significant in all tests. At least three experiments were 
performed in all assays and for each culture. Data were expressed as 
means ± standard deviation (SD).
3  |  RESULTS
Flow cytometry showed that a high percentage of the HAT cells iso-
lated and characterized as MSCs had phagocytic capacity ranging 
from 33.8% to 56.2% (44.37% ± 11.253), according to the cell line. 
The mean channel fluorescence was also elevated in all three lines, 
ranging between 4314 and 4973 (4619 ± 0.332), indicating a high 
phagocytic index (Figure 1; Table 1).
Transmission electron microscopy confirmed the results ob-
tained by flow cytometry, demonstrating the capacity of the cells 
to internalize the target particles under study and ruling out the 
possibility that the detected fluorescence derived from the adhe-
sion of latex beads to the cell surface. The images in Figure 2 de-
pict the ultrastructure of HAT- MSCs (pronounced cytoskeleton, 
abundant mitochondria, rough endoplasmic reticulum, nucleus with 
two prominent nucleoli, etc.), the ultrastructure of the same cells in 
culture and after incubation with biological (C. albicans; E. coli; and 
S. aureus) or synthetic (latex beads) particles. It is observed abundant 
lipid drops, as a consequence of the origin of the line; the presence 
of multivesicular bodies, residues of the digestion of the biologi-
cal material (microorganisms); and the phagosomes containing the 
phagocytosed target particle inside. Figure 3 shows micrographs of 
HAT- MSC incubated for 24 h with various target particles, showing 
different stages of the phagocytic process with adhesion, engulf-
ment, phagosomes and multivesicular bodies. The high phagocytic 
index observed is noteworthy, especially when cells were cultured 
with latex beads (Figure 4).
F I G U R E  1  Fluorescence histogram 
obtained by analysing the phagocytic 
capacity of HAT- MSCs using the flow 
cytometry technique. (A) Incubated 
with FITC- labelled latex beads at 4°C 
(control). (B) Incubated with FITC- labelled 
latex beads at 37°C (study group). This 
figure shows the results of one of the 
experiments
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4  |  DISCUSSION
This study demonstrated the phagocytic capacity against different 
target particles of cells isolated from HAT samples and characterized 
as MSCs.
Flow cytometry studies confirmed the capacity of a high per-
centage of HAT- MSCs to phagocytose latex beads, large numbers of 
which were ingested by the cells. These data are consistent with re-
ports of the same functional capacity for other cell populations that 
differentiate from MSCs, including osteoblasts, cells of mesenchy-
mal origin that derive from osteoprogenitors.44– 46 In the osteoblast, 
this phagocytic activity can be modulated by biological factors, 
drugs or physical agents.47– 49 Preadipocytes and adipocytes, also of 
mesenchymal origin, express a wide spectrum of TLRs, and preadi-
pocytes can become macrophage- like cells.50 TLR2 is expressed in 
early stages of adipocyte differentiation and TLR9 in later stages of 
this process. In addition, TLR2 synthesis can be stimulated by bac-
terial lipopolysaccharides (LPS), zymosan from yeast cell wall, and 
murine or human adipocyte tumour growth factor.51
Flow cytometry is a fast and simple technique that yields a 
large amount of data on a cell population, including functional in-
formation, allowing quantification of its phagocytic capacity and 
the higher or lower number of particles that a cell can phagocy-
tose according to the fluorescence intensity observed. However, 
F I G U R E  2  Transmission electron microscopy study of HTA- MSCs cells cultured with different target particles. (A) HAT- MSCs in culture 
(control, without target particles): (B) HAT- MSC incubated for 24 h at 37°C with: (B1) C. albicans; (B2) E. coli; (B3) S. aureus; or (B4) latex 
beads. Different cellular elements (cytoskeleton, mitochondria, rough endoplasmic reticulum, nucleus and nucleoli) are also pointed out in 
figures
(A) (B1) (B2) (B3) (B4)
(A) (B1) (B2) (B3) (B4)





% SD p Mean SD p
Control group (4°C) 4.62 0.332 — 1.313 0.134 — 
Study group (37°C) 44.37 11.253 0.004* 4.619 0.332 0.001*
Note: Results are expressed as mean ± SD and percentage of cells that have phagocytic capacity 
as well as the mean ± SD of the average value of fluorescence intensity. Comparisons of data 
between study group and control group were evaluated by Student's t test. At least three 
experiments were performed in all assays and for each culture.
Abbreviation: SD, standard deviation.
*p ≤ 0.05 significant difference.
TA B L E  1  Phagocytic capacity of HAT- 
MSCs determined by flow cytometry 
analysis
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non- specific binding to the cell surface can give rise to false posi-
tives, even when the appropriate negative controls are used.52 For 
this reason, the most rigorous method to confirm this functional 
capacity in a population, ruling out false positives, is to incubate 
cells in the presence of a target particle and then analyse the cells 
by transmission electron microscopy. This offers visualization of 
the internalized particles, the phagosome and the degree of diges-
tion of the particle it contains.
Our transmission electron microscopy results show the ultra-
structure of HAT- MSCs, as previously described Pasquinelli et al.53 
in MSCs from different origins. Moreover, we verified the capacity 
of HAT- MSCs to phagocytose both non- biological (latex) and biolog-
ical (microorganisms) materials. Thus, the technique also confirmed 
the high phagocytic index observed by flow cytometry, especially 
when the target particles were latex. The biological targets included 
one Gram- negative and one Gram- positive bacterium and one yeast. 
These microorganisms have been selected for their structural and 
size differences, as well as for being prevalent microorganisms in in-
fectious processes.
Khan et al. recently reported that MSCs isolated from human 
bone marrow or umbilical cord can phagocytose Mycobacterium tu-
berculosis (Mtb).23 For this purpose, bacteria marked with a green 
fluorescent protein (gfp) were incubated with MSCs and subse-
quently analysed by fluorescence microscopy. However, the authors 
acknowledged that the Mtb uptake mechanisms are unclear. In 
contrast to other phagocytic cells, there are fewer known receptors 
in MSCs that could be involved in particle uptake. At least two types 
of SR (MARCO and SR- B1) appear to mediate in the uptake of Mtb 
but not of MRs in MSCs. Thus, a marked inhibition of Mtb uptake 
was observed in MSCs treated with a combination of antibodies 
against MARCO and SR- B1, although a role for other receptors was 
not ruled out.23 In this line, treatment with LPS, which activate TLR- 
4, was found to induce osteogenic differentiation in MSCs, while 
dsRNA activated TLR- 3 and improved stem cell migration.22
Other studies show how MSCs can produce factors with bac-
tericidal activity54,55; act synergistically with antibiotics to generate 
bactericidal activity56,57; alter the expression of antimicrobial pep-
tides and the production of cytokines, through their activation by 
innate immune pathways58; influence on the formation of the bio-
film55,59; and stimulate phagocytosis by neutrophils.55
Although the action of MSCs against infection is not well docu-
mented, they have been attributed with an immunomodulatory role 
in both the innate and adaptive response through their effects on 
numerous cell types, including neutrophils, dendritic cells, Natural 
Killer cells, B lymphocytes, T lymphocytes and regulatory T cells.60– 62
With regard to the immunological role of adipose tissue stem 
cells, this population has an immunomodulatory character in tumour 
immune response processes,63,64 as well as in certain immunological 
inflammatory processes in wound healing.65,66 Recent studies have 
revealed the immune- mediating capacity of both adipose tissue stem 
F I G U R E  3  Transmission electron 
micrographs of HAT- MSCs incubated 
for 24 h at 37°C with target particles, 
showing the different stages of the 
phagocytic process. (A) Adherence/
binding; (B) phagosome; (C) 
phagolysosome; and (D) residual body
(A) (B)
(C) (D)
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cells and vascular fraction stem cells in COVID- 19 disease.38,67,68 In 
this sense, an in vivo study detected how MSCs administered in-
travenously can promote an increase in peripheral blood lympho-
cytes, a decrease in C- reactive protein and a decrease in certain cell 
groups responsible for the release of pro- inflammatory cytokines in 
patients infected by SARS- CoV- 2.69 Thus, and considering the pos-
sible phagocytic capacity and the different immunological proper-
ties of HAT- MSCs, its use in certain inflammatory processes, such 
as infectious processes, may represent an important advance in the 
approach and treatment of certain pathologies.
Our demonstration of the phagocytic capacity of HAT- MSCs 
supports the immunomodulatory role of these cells and indicates 
the need for more detailed research on this function, its possible 
clinical relevance and its action on other cell populations.
In summary, HAT- MSCs have phagocytic capacity against differ-
ent microorganisms and against non- biological material. MSCs are 
known to have major therapeutic potential for regeneration and for 
the treatment of infections. These new data on their functional ca-
pacity expands our knowledge of MSCs and their potential clinical 
relevance.
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